Clinical outcomes depend on dose titration, adherence, and individual genetic factorsnot the brand or compounded source
Adults with a BMI of 30 or more, or a BMI of 27 coupled with at least one weight-related health condition such as hypertension or sleep apnea, may benefit from our treatments
By checking this box, you agree to our Privacy Policy which discusses, in particular, what information we collect, how we use it, and how to opt-out.* Request an Appointment After submitting, a member of our staff will be in touch with you to confirm an appointment
It walks through the actual research on GHK-Cu what it shows, what it doesn't show, and how confident you should be in each tier of evidence
A person with type 2 diabetes who struggles to lower blood sugar even though lifestyle work may benefit from GLP 1 therapy
Future prospective studies are needed to explore whether baseline or dynamic incretin profiles can serve as biomarkers for responsiveness to adjunct pharmacotherapy